Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
作者信息
Lange Christoph, Barry Clifton E, Horsburgh C Robert
机构信息
Division of Clinical Infectious Diseases Research Center Borstel Borstel, Germany.
Clinical Tuberculosis Unit German Center for Infection Research (DZIF) Borstel, Germany.
出版信息
Am J Respir Crit Care Med. 2022 May 15;205(10):1142-1144. doi: 10.1164/rccm.202202-0393ED.
Abstract
摘要
相似文献
1
Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
Am J Respir Crit Care Med. 2022 May 15;205(10):1142-1144. doi: 10.1164/rccm.202202-0393ED.
2
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Int J Tuberc Lung Dis. 2002 Aug;6(8):649-50.
3
WHO recommendations for multidrug-resistant tuberculosis - Authors' reply.
Lancet. 2016 Nov 5;388(10057):2234-2235. doi: 10.1016/S0140-6736(16)31465-9.
4
Multidrug-resistant tuberculosis in children can be treated.
Lancet Infect Dis. 2012 Jun;12(6):425-6. doi: 10.1016/S1473-3099(12)70038-5. Epub 2012 Feb 27.
5
Number of drugs to treat multidrug-resistant tuberculosis.
Am J Respir Crit Care Med. 2004 Jun 15;169(12):1336-7; author reply 1337. doi: 10.1164/ajrccm.169.12.965.
6
[Advances in the study of chemotherapy of multidrug-resistant tuberculosis].
Zhonghua Jie He He Hu Xi Za Zhi. 2009 Aug;32(8):617-20.
7
[Discussing on multidrug-resistant tuberculosis for surgery].
Zhonghua Jie He He Hu Xi Za Zhi. 2019 May 12;42(5):338-342. doi: 10.3760/cma.j.issn.1001-0939.2019.05.006.
8
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
N Engl J Med. 2016 Dec 29;375(26):2611. doi: 10.1056/NEJMc1613123.
9
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
N Engl J Med. 2016 Dec 29;375(26):2610. doi: 10.1056/NEJMc1613123.
10
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
N Engl J Med. 2016 Dec 29;375(26):2609. doi: 10.1056/NEJMc1613123.
引用本文的文献
1
Leveraging insights from cancer to improve tuberculosis therapy.
Trends Mol Med. 2025 Jan;31(1):11-20. doi: 10.1016/j.molmed.2024.07.011. Epub 2024 Aug 13.
2
Repurposing of anti-malarial drugs for the treatment of tuberculosis: realistic strategy or fanciful dead end?
Malar J. 2024 May 3;23(1):132. doi: 10.1186/s12936-024-04967-2.
3
Treatment-shortening regimens for tuberculosis: updates and future priorities.
Breathe (Sheff). 2023 Sep;19(3):230028. doi: 10.1183/20734735.0028-2023. Epub 2023 Oct 10.
4
Effect of Low Doses of Dexamethasone on Experimental Pulmonary Tuberculosis.
Microorganisms. 2023 Jun 10;11(6):1554. doi: 10.3390/microorganisms11061554.
5
New treatments for Drug Resistant TB: Past imperfect, future bright.
Lung India. 2023 Jan-Feb;40(1):1-3. doi: 10.4103/lungindia.lungindia_556_22.
本文引用的文献
1
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
Am J Respir Crit Care Med. 2022 May 15;205(10):1228-1235. doi: 10.1164/rccm.202108-1976OC.
2
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Am J Respir Crit Care Med. 2022 May 15;205(10):1214-1227. doi: 10.1164/rccm.202107-1779OC.
3
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12.
4
Emergence of bedaquiline resistance in a high tuberculosis burden country.
Eur Respir J. 2022 Mar 24;59(3). doi: 10.1183/13993003.00621-2021. Print 2022 Mar.
5
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Nat Med. 2021 Aug;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2.
6
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
Eur Respir J. 2021 Apr 8;57(4). doi: 10.1183/13993003.00361-2021. Print 2021 Apr.
7
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
Eur Respir J. 2021 Jun 4;57(6). doi: 10.1183/13993003.03300-2020. Print 2021 Jun.
8
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
9
Management of drug-resistant tuberculosis.
Lancet. 2019 Sep 14;394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3.
10
Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
Respirology. 2018 Jul;23(7):656-673. doi: 10.1111/resp.13304. Epub 2018 Apr 11.
Zotero 插件